ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志

• 论文 • 上一篇    下一篇

靶向清除B细胞治疗系统性红斑狼疮

  

  • 出版日期:2020-02-28 发布日期:2020-03-19

B cell depletion therapy in  treatment of systemic lupus erythematosus

  • Online:2020-02-28 Published:2020-03-19

摘要: 系统性红斑狼疮 (SLE)是一种多系统受累的自身免疫性疾病,可危及生命。B细胞对自身抗原的耐受丢失,进而产生自身抗体是该病的重要发病机制。目前,糖皮质激素与细胞毒类药物、钙调蛋白酶抑制剂是主要的治疗手段,然而,仍有部分患者对治疗反应不佳或反复复发。近年来,特异性针对B细胞耗竭的治疗方案逐渐成为SLE治疗的一个重要策略和研究方向。利妥昔单抗的应用更佐证了这类疗法的可行性及可观前景。本文就B细胞在SLE发病机制中的作用,以及B细胞耗竭理论在相关基础和临床研究中的进展作一综述,为进一步探讨嵌合抗原受体T细胞疗法治疗此类疾病的可行性和研究方向提供科研设想依据。

关键词: 系统性红斑狼疮, B细胞, 利妥昔单抗, 嵌合抗原受体T细胞

Abstract: Systemic lupus erythematosus (SLE) is an autoimmune disease with multiple system involvement.The pathogenesis of SLE is characterized by  loss of B cell selftolerance to autoantigen  production of autoantibodies.Currently,the main choice in treating SLE are  glucocorticoids,cytotoxic agents and calcineurin inhibitors.However,there are still some patients with poor response to treatment or recurrence.In recent years,B cell clearance specifically has gradually become an important strategy and research field in SLE treatment.The feasibility and prospects of this strategy is further comfirmed by the clinical expeience of rituximabIn this review,we will discuss the role of B cell and the current situation of B cell depletion stategy in SLE.The feasibility of Chimeric antigen receptorT cell  (CART cell) therapy  in SLE will be further explored.